CDKN1A Human siRNA Oligo Duplex (Locus ID 1026)

CAT#: SR300740

CDKN1A (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each

Specifications

Product Data

• Purity: HPLC purified
• Quality Control: Tested by ESI-MS
• Sequences: Available with shipment
• Components: CDKN1A (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1026)
  Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
  Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
• Stability: One year from date of shipment when stored at -20°C.
• Number of Transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
• Note: Single siRNA duplex (10nmol) can be ordered.

Reference Data

• RefSeq: NM_000389, NM_001220777, NM_001220778, NM_001291549, NM_078467, NR_037150, NR_037151, NR_037152
• Synonyms: CAP20; CDKN1; CIP1; MDA-6; P21; p21CIP1; SDI1; WAF1
• Summary: 'This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lack this gene have the ability to regenerate damaged or missing tissue. Multiple alternatively spliced variants have been found for this gene. [provided by RefSeq, Sep 2015]'
• Performance Guaranteed: OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.
  
  For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).